The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study

References

• Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45:21-8
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31
   PubMed Web of Science ®Google Scholar
• Curkendall SM, Mo J, Glasser DB, et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004;65:715-20
   PubMed Web of Science ®Google Scholar
• Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171:502-8
   PubMed Web of Science ®Google Scholar
• Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006;3:A42
   PubMedGoogle Scholar
• Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-21
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007;298:1794-6
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165:2644-50
   PubMed Web of Science ®Google Scholar
• Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord 2009;7:279-88
   PubMed Web of Science ®Google Scholar
• Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005;47:201-10
   PubMed Web of Science ®Google Scholar
• Barnett AH, Mackin P, Chaudhry I, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007;21:357-73
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
   PubMed Web of Science ®Google Scholar
• Cohn T, Prud’homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-60
   PubMed Web of Science ®Google Scholar
• Basu R, Brar JS, Chengappa KN, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder – bipolar subtype. Bipolar Disord 2004;6:314-18
   PubMed Web of Science ®Google Scholar
• De Hert MA, van WR, Van ED, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93
   PubMed Web of Science ®Google Scholar
• Rezaei O, Khodaie-Ardakani MR, Mandegar MH, et al. Prevalence of metabolic syndrome among an Iranian cohort of inpatients with schizophrenia. Int J Psychiatry Med 2009;39:451-62
   PubMed Web of Science ®Google Scholar
• Bou KR, Rohayem J, Abou SN, et al. Metabolic syndrome (MetS) in Lebanese patients with schizophrenia receiving atypical antipsychotic drugs. Asian J Psychiatr 2013;6:88-9
   PubMedGoogle Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Kane JM, et al. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006;67:575-83
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-9
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19-28
   PubMed Web of Science ®Google Scholar
• Koro CE, Fedder DO, L’Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-6
   PubMed Web of Science ®Google Scholar
• Chen Y, Bobo WV, Watts K, et al. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. J Psychopharmacol 2012;26:1201-10
   PubMed Web of Science ®Google Scholar
• Pappadopulos E, Newcomer JW, Kolluri S. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of Pfizer-initiated clinical trials. J Clin Psychiatry 2012;73:e742-8
   PubMedGoogle Scholar
• Montes JM, Rodriguez JL, Balbo E, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:383-8
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008;33:985-94
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text-Revised (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000
   Google Scholar
• Zeldox Canada Package Insert. Kirkland, Quebec, Canada: Pfizer Canada Inc., 2011
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology Revised Edition. Rockville, MD: National Institute of Mental Health, 1976
   Google Scholar
• Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-83
   PubMed Web of Science ®Google Scholar
• De HM, Hanssens L, van WR, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007;33:823-30
   PubMed Web of Science ®Google Scholar
• Stroup TS, Byerly MJ, Nasrallah HA, et al. Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res 2013;146:190-5
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24(5 Suppl 1):S7-14
   PubMedGoogle Scholar
• Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6
   PubMed Web of Science ®Google Scholar
• Kato MM, Goodnick PJ. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother 2001;2:1571-82
   PubMedGoogle Scholar
• De Hert MA, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-24
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004;24(5 Suppl 1):S1-6
   PubMedGoogle Scholar
• Chue P. The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective. Can J Psychiatry 2004;49:200-7
   PubMed Web of Science ®Google Scholar